Exchange: NASDAQ·Updated 07:30 PM EDT
IRON logo

IRON Disc Medicine Inc

$62.06
$1.29
(2.12%)
Today
Closed $62.06
$0.00
(0.00%)
After Hours
EarningsNov 5
Mkt Cap$2.33B
Vol691,135.00

About IRON

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.
31

Bearish Sentiment

How do you feel about IRON?

Trainguy1
$IRON Disc Medicine expects to have a lot of news and information to share in Q4: - Bitopertin (Erythropoietic Porphyrias - EPP/XLP): Topline data from the fully enrolled Phase 3 APOLLO Trial are expected in Q4 2026, which will serve as the basis to support traditional approval. - DISC-0974 / Selcodibar (Myelofibrosis Anemia): Topline Phase 2 RALLY-MF data updates and an End-of-Phase 2 meeting with the FDA are anticipated in H2 2026 / Q4 2026. - DISC-3405 (Polycythemia Vera & Sickle Cell Disease): Initial clinical data from the Phase 2 study in polycythemia vera and the Phase 1b study in sickle cell disease are expected in Q4 2026.
3
peloswing
$IRON $75 calls for Nov. 20th - $468,000+ net buying The stock has a $102.58 average price target: 48.46% higher 🟢
2
justiceforb_85
$IRON main catalyst for Q4 is bitopertin P3 data. We'll see if lowering PPIX levels results in a clinically meaningful change in sunlight tolerance. Lean positive.

Advertisement|Remove ads.